Breaking News Instant updates and real-time market news.

TEVA

Teva

$31.84

-1.35 (-4.07%)

, AZN

AstraZeneca

$33.71

1.32 (4.08%)

14:08
07/14/17
07/14
14:08
07/14/17
14:08

Teva sinks after Bloomberg says AstraZeneca CEO staying put

Shares of Teva Pharmaceutical Industries (TEVA) are moving lower after Bloomberg reported, citing people with knowledge of the matter, that AstraZeneca (AZN) CEO Pascal Soriot plans on staying with the company for the foreseeable future. Bloomberg's report disputes Israel's Calcalist, which said Wednesday night that Soriot is expected to leave AstraZeneca and become the next CEO of Teva. Following the report, shares of Teva are down 4% to $31.78 while AstraZeneca is up 4% to $33.58.

TEVA

Teva

$31.84

-1.35 (-4.07%)

AZN

AstraZeneca

$33.71

1.32 (4.08%)

  • 19

    Jul

  • 03

    Aug

  • 30

    Aug

TEVA Teva
$31.84

-1.35 (-4.07%)

06/27/17
WELS
06/27/17
NO CHANGE
WELS
Market Perform
Teva TV-45070 trial miss a 'modest disappointment,' says Wells Fargo
Wells Fargo analyst David Maris said TV-45070 has not been a focus for Teva (TEVA) investors, but he still views the news that the company and partner Xenon Pharmaceuticals' (XENE) Phase 2 trial in post-herpetic neuralgia missed its primary endpoint as a "modest disappointment" given the need for Teva's pipeline to offset the tough generic market and the eventual competition for Copaxone. Maris keeps a Market Perform rating on Teva.
07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
AZN AstraZeneca
$33.71

1.32 (4.08%)

07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.

TODAY'S FREE FLY STORIES

CLXT

Calyxt

10:39
07/20/17
07/20
10:39
07/20/17
10:39
Syndicate
Breaking Syndicate news story on Calyxt »

Calyxt opens at $9.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

BG

Bunge

$77.21

-1.48 (-1.88%)

10:36
07/20/17
07/20
10:36
07/20/17
10:36
Hot Stocks
Bunge has positive expectations for 2H 7 in agribusiness »

Positive expectations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 02

    Aug

  • 14

    Aug

SPX

S&P 500

10:36
07/20/17
07/20
10:36
07/20/17
10:36
General news
Mueller expands investigation into Trump's businesses, Bloomberg reports »

Special Counsel Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$51.66

1.45 (2.89%)

10:34
07/20/17
07/20
10:34
07/20/17
10:34
Hot Stocks
Garmin acquires privately held Alphamantis Technologies; terms not disclosed »

Garmin Ltd. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

BG

Bunge

$77.16

-1.5283 (-1.94%)

10:33
07/20/17
07/20
10:33
07/20/17
10:33
Hot Stocks
Bunge sees Q2 adjusted net income below low end of range of estimates »

Q2 2017 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 02

    Aug

  • 14

    Aug

10:30
07/20/17
07/20
10:30
07/20/17
10:30
General news
EIA natural gas storage change for week ending July 14 »

Gas inventories 28 Bcf…

CHRW

C.H. Robinson

$68.69

-0.81 (-1.17%)

10:30
07/20/17
07/20
10:30
07/20/17
10:30
Options
Put buyers in CH Robinson as shares fall on earnings »

Put buyers in CH Robinson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

10:30
07/20/17
07/20
10:30
07/20/17
10:30
General news
Today's U.S. reports »

Today's U.S. reports…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:29
07/20/17
07/20
10:29
07/20/17
10:29
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics says very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

XOM

Exxon Mobil

$81.30

0.45 (0.56%)

10:29
07/20/17
07/20
10:29
07/20/17
10:29
Periodicals
Exxon Mobil fined $2M over Ukraine-related sanctions violations, Reuters says »

The U.S. Treasury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$146.69

-6.615 (-4.32%)

, LOW

Lowe's

$73.43

-3.4 (-4.43%)

10:27
07/20/17
07/20
10:27
07/20/17
10:27
Recommendations
Home Depot, Lowe's analyst commentary  »

Home Depot and…

HD

Home Depot

$146.69

-6.615 (-4.32%)

LOW

Lowe's

$73.43

-3.4 (-4.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

, NUE

Nucor

$58.99

-1.67 (-2.75%)

10:27
07/20/17
07/20
10:27
07/20/17
10:27
Hot Stocks
Steel Dynamics CEO says flat rolled enviroment steady despite auto »

Industry will follow…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

NUE

Nucor

$58.99

-1.67 (-2.75%)

X

U.S. Steel

$24.08

-0.39 (-1.59%)

AKS

AK Steel

$6.52

-0.08 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 20

    Jul

  • 25

    Jul

  • 26

    Jul

PFE

Pfizer

$33.60

-0.025 (-0.07%)

, MRK

Merck

$63.18

0.555 (0.89%)

10:26
07/20/17
07/20
10:26
07/20/17
10:26
Hot Stocks
Credit Suisse cuts Pfizer to hold, prefers Merck, J&J »

Credit Suisse downgraded…

PFE

Pfizer

$33.60

-0.025 (-0.07%)

MRK

Merck

$63.18

0.555 (0.89%)

JNJ

Johnson & Johnson

$136.04

0.83 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 27

    Aug

  • 22

    Sep

10:25
07/20/17
07/20
10:25
07/20/17
10:25
General news
U.S. leading economic index rose 0.6% to 127.8 in June »

U.S. leading economic…

C

Citi

$66.79

0.09 (0.13%)

10:25
07/20/17
07/20
10:25
07/20/17
10:25
Conference/Events
Citigroup to hold a conference call »

CFO Gerspach holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 25

    Jul

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Citi awaits better Tesla entry point as bulls, bears both make good points »

Citi analyst Itay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 02

    Oct

VRTX

Vertex

$159.69

27.53 (20.83%)

10:20
07/20/17
07/20
10:20
07/20/17
10:20
Options
Large call spread in Vertex Pharm after yesterday's surge »

Large call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

10:20
07/20/17
07/20
10:20
07/20/17
10:20
General news
Treasury Action: longer yields rotated lower again »

Treasury Action: longer…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

, JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

TSLA

Tesla

$325.26

-2.98 (-0.91%)

JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

TTS

Tile Shop

$14.83

-0.175 (-1.17%)

SBPH

Spring Bank Pharmaceuticals

$14.20

-0.12 (-0.84%)

DISCA

Discovery

$27.18

1.13 (4.34%)

SNI

Scripps Networks

$76.89

9.87 (14.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 09

    Aug

  • 09

    Aug

  • 02

    Oct

PFE

Pfizer

, RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

PFE

Pfizer

RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

FMSA

Fairmount Santrol

$3.63

-0.245 (-6.33%)

NEWR

New Relic

$47.96

-0.84 (-1.72%)

SND

Smart Sand

$7.87

0.25 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 08

    Aug

  • 27

    Aug

  • 29

    Aug

NKE

Nike

$59.31

1.54 (2.67%)

, BGS

B&G Foods

$37.08

1.275 (3.56%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$59.31

1.54 (2.67%)

BGS

B&G Foods

$37.08

1.275 (3.56%)

HPQ

HP Inc.

$18.86

0.155 (0.83%)

RCL

Royal Caribbean

$115.14

2.5775 (2.29%)

BWLD

Buffalo Wild Wings

$122.60

0.65 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 29

    Aug

  • 11

    Sep

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Hot Stocks
Steel Dynamics sees more stabilized scrap environment in 2H »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

$NSD

NASDAQ Market Internals

10:17
07/20/17
07/20
10:17
07/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.